Cannabis in pregnancy: Difference between revisions
Created page with "{{short description|Effects of cannabis consumption during pregnancy}} {{Cannabis sidebar}} '''Cannabis consumption in pregnancy''' is an important public health issue. Research has found possible or likely associations between cannabis use and a risk of adverse outcomes in respect of cognitive development, mental health, physical health, and lactation. Cannabis is the most commonly used controlled substance among pregnant women. ==Endocannabinoid system== {{See al..." |
No edit summary |
||
| Line 1: | Line 1: | ||
<languages /> | |||
<translate> | |||
{{short description|Effects of cannabis consumption during pregnancy}} | {{short description|Effects of cannabis consumption during pregnancy}} | ||
{{Cannabis sidebar}} | {{Cannabis sidebar}} | ||
| Line 9: | Line 11: | ||
The role of the endocannabinoid system (ECS) in female fertility has long been suspected and studied. Most studies through 2013 linking development of the fetus and cannabis show effects of consumption during the gestational period, but abnormalities in the endocannabinoid system during the phase of placental development are also linked with problems in pregnancy. According to Sun and Dey (2012), endocannabinoid signaling plays a role in "female reproductive events, including preimplantation embryo development, oviductal embryo transport, embryo implantation, placentation, and parturition". Karusu ''et al'' (2011) said that a "clear correlation ... in the actual reproductive tissues of miscarrying versus healthy women has yet to be established. However, the adverse effects of marijuana smoke and THC on reproductive functions point to processes that are modulated by ECS.". | The role of the endocannabinoid system (ECS) in female fertility has long been suspected and studied. Most studies through 2013 linking development of the fetus and cannabis show effects of consumption during the gestational period, but abnormalities in the endocannabinoid system during the phase of placental development are also linked with problems in pregnancy. According to Sun and Dey (2012), endocannabinoid signaling plays a role in "female reproductive events, including preimplantation embryo development, oviductal embryo transport, embryo implantation, placentation, and parturition". Karusu ''et al'' (2011) said that a "clear correlation ... in the actual reproductive tissues of miscarrying versus healthy women has yet to be established. However, the adverse effects of marijuana smoke and THC on reproductive functions point to processes that are modulated by ECS.". | ||
Recent data indicates that endometrial expression of cannabinoid receptors in marijuana smoking mothers is higher than non-smokers. Keimpema and colleagues (2011) said, "Prenatal cannabis exposure can lead to growth defects during formation of the nervous system"; "[c]annabis impacts the formation and functions of neuronal circuitries by targeting cannabinoid receptors ... By indiscriminately prolonging the "switched-on" period of cannabinoid receptors, cannabis can hijack endocannabinoid signals to evoke molecular rearrangements, leading to the erroneous wiring of neuronal networks". A report prepared for the [[Australian National Council on Drugs]] concluded cannabis and other [[cannabinoid]]s are contraindicated in pregnancy as they may interact with the endocannabinoid system. | Recent data indicates that endometrial expression of cannabinoid receptors in marijuana smoking mothers is higher than non-smokers. Keimpema and colleagues (2011) said, "Prenatal cannabis exposure can lead to growth defects during formation of the nervous system"; "[c]annabis impacts the formation and functions of neuronal circuitries by targeting cannabinoid receptors ... By indiscriminately prolonging the "switched-on" period of cannabinoid receptors, cannabis can hijack endocannabinoid signals to evoke molecular rearrangements, leading to the erroneous wiring of neuronal networks". A report prepared for the [[Australian National Council on Drugs]] concluded cannabis and other [[cannabinoid]]s are contraindicated in pregnancy as they may interact with the endocannabinoid system. | ||
==Evidence== | ==Evidence== | ||
| Line 49: | Line 51: | ||
[[Category:Drugs and pregnancy]] | [[Category:Drugs and pregnancy]] | ||
{{二次利用|date=17 July 2025, at 18:05}} | {{二次利用|date=17 July 2025, at 18:05}} | ||
</translate> | |||